Novo Nordisk Launches Blockbuster Weight-Loss Drug Ozempic in India

Danish pharmaceutical company Novo Nordisk has introduced the once-weekly injectable drug Ozempic in India, stepping up its presence in a country with high prevalence of type 2 diabetes and rising obesity rates.  

The launch comes as demand grows for modern therapies that address both blood glucose control and weight management.  

Key Development: Ozempic Now Available with 3 Doses 

According to news reports, Ozempic will be sold in India in three dosing strengths 0.25 mg, 0.5 mg and 1 mg following regulatory approval earlier in the year.  

The lowest dose has been priced at ₹2,200 per week, which translates to ₹8,800 per month, while the 0.5 mg and 1 mg doses are priced at approximately ₹10,170 and ₹11,175 per month, respectively.  

The diabetes treatment, which has been widely used globally for type 2 diabetes since its approval in 2017, is also recognised for its appetite-suppressing effects, leading to off-label use for weight loss in several markets.   

India, with the 2nd-highest number of adults living with type 2 diabetes worldwide and rising obesity levels, presents a key opportunity for the product.  

Market Context: Broader Industry Trends 

India’s diabetes and weight-management sector has become a competitive landscape for global drugmakers.  

 Novo Nordisk previously launched Wegovy, another semaglutide-based product designed specifically for chronic weight management, while competitors such as Eli Lilly have brought their own GLP-1-class drugs, including Mounjaro, to the market.  

The timing of the Ozempic launch also precedes the upcoming patent expiry of semaglutide in early 2026, which is expected to open the door for generic versions from domestic manufacturers.  

Read More: Novo Nordisk India and Healthify Partners to Launch AI Enabled Patient Support Programme! 

Conclusion 

The launch of Ozempic in India underscores Novo Nordisk’s strategic focus on a major market with a large burden of diabetes and growing demand for effective weight-related therapies.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.